Showing 1‐20 of 500
06 Nov 2023
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
Basel, Switzerland, 06 November 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 400 million...
17 Oct 2023
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
At its Capital Markets Day, Lonza outlined its Mid-Term Guidance for 2024 to 2028, including: 11–13% sales growth, 32–34% CORE EBITDA margin and double-digit ROIC Outlook 2023:...
16 Oct 2023
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
New agreement to establish global commercial manufacturing capacity for Vaxcyte's PCV candidates, VAX-24 and VAX-31, in adult and pediatric populations Expanded collaboration...
13 Oct 2023
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercial supply Expansion of filling capacity will enhance Lonza's...
05 Oct 2023
Lonza Further Extends Collaboration with Major Biopharmaceutical Partner for Manufacturing Antibody-Drug Conjugates
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat...
21 Sep 2023
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
Capital Markets Day 2023 will be hosted by members of the Lonza Executive Committee The presentation will provide an overview of Lonza’s offerings, capabilities, markets and...
18 Sep 2023
CEO Pierre-Alain Ruffieux to leave Lonza Albert M. Baehny to step in as CEO ad interim Capital Markets Day on October 17 confirmed Basel, Switzerland, 18 September 2023 –...
21 Jul 2023
Lonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin
In H1 2023, Lonza delivered CHF 3.1 billion sales and 5.6% CER1 sales growth, corresponding to around 10% CER underlying sales growth2 CHF 922 million CORE EBITDA resulted in a...
Cell & Gene
26 Jun 2023
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
Following positive Phase 1/2 results in Vertex’s VX-880 program, Vertex and Lonza announce strategic manufacturing collaboration Dedicated large-scale facility will support...
01 Jun 2023
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition will further strengthen Lonza’s bioconjugates offering...
16 May 2023
Lonza Prices EUR 500 Million Straight Bond with a 3.875% Coupon
Basel, Switzerland, 16 May 2023 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a EUR 500 million...
10 May 2023
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
Robust commercial demand, with softer early-stage demand due to biotech funding constraints Growth project portfolio progressing in line with plan Outlook 2023 reiterated,...
05 May 2023
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Shareholders re-elected all existing members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of Directors A dividend of CHF 3.50 per share...
20 Apr 2023
Lonza Increases Straight Bond by CHF 150 Million
Basel, Switzerland, 20 April 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the increase of the Straight Bond issued...
31 Mar 2023
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Basel, Switzerland, 31 March 2023 – On 3 April 2023, Lonza will launch a share buyback program of up to CHF 2 billion, as announced on 25 January 2023. Enabled by Lonza’s strong...
29 Mar 2023
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Lonza increases capacity and capabilities in Visp (CH) with the completion of a new line for cGMP clinical and commercial drug product manufacturing The line is fully...
27 Mar 2023
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
Annual General Meeting to take place on 5 May 2023 at the Congress Center in Basel, Switzerland Albert M. Baehny proposed for re-election as Chairman of the Board of...
16 Feb 2023
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates The Visp (CH) investment...
08 Feb 2023
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
Basel, Switzerland, 08 February 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 300 million...